Amylyx Pharmaceuticals (AMLX) Stock Forecast, Price Target & Predictions
AMLX Stock Forecast
Amylyx Pharmaceuticals stock forecast is as follows: an average price target of $3.33 (represents a 27.10% upside from AMLX’s last price of $2.62) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
AMLX Price Target
The average price target for Amylyx Pharmaceuticals (AMLX) is $3.33 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $4.00 to $3.00. This represents a potential 27.10% upside from AMLX's last price of $2.62.
AMLX Analyst Ratings
According to 3 Wall Street analysts, Amylyx Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for AMLX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Amylyx Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 14, 2024 | Graig Suvannavejh | Mizuho Securities | $3.00 | $1.82 | 64.84% | 14.50% |
| Apr 11, 2024 | Joel Beatty | Robert W. Baird | $3.00 | $2.46 | 21.95% | 14.50% |
| Apr 04, 2024 | Neena Bitritto-Garg | Deutsche Bank | $4.00 | $2.62 | 52.96% | 52.67% |
| Mar 17, 2024 | Graig Suvannavejh | Mizuho Securities | $4.00 | $3.24 | 23.46% | 52.67% |
The latest Amylyx Pharmaceuticals stock forecast, released on May 14, 2024 by Graig Suvannavejh from Mizuho Securities, set a price target of $3.00, which represents a 64.84% increase from the stock price at the time of the forecast ($1.82), and a 14.50% increase from AMLX last price ($2.62).
Amylyx Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $3.50 |
| Last Closing Price | $2.62 | $2.62 | $2.62 |
| Upside/Downside | -100.00% | -100.00% | 33.59% |
In the current month, the average price target of Amylyx Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Amylyx Pharmaceuticals's last price of $2.62. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 12, 2024 | Goldman Sachs | Underperform | Underperform | Hold |
| Jul 11, 2024 | Goldman Sachs | Neutral | Neutral | Hold |
| Jun 24, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 08, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 08, 2024 | Goldman Sachs | Underperform | Underperform | Hold |
| Apr 04, 2024 | Deutsche Bank | Buy | Buy | Hold |
| Mar 14, 2023 | Citigroup | Buy | Buy | Hold |
| Jun 23, 2022 | Citigroup | Buy | Buy | Hold |
Amylyx Pharmaceuticals's last stock rating was published by Goldman Sachs on Jul 12, 2024. The company gave AMLX a "Underperform" rating, the same as its previous rate.
Amylyx Pharmaceuticals Financial Forecast
Amylyx Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $102.69M | - | $71.43M | $21.89M | $345.00K | - | - | - |
| Avg Forecast | $44.60M | $47.55M | $52.43M | $58.15M | $32.59M | $31.57M | $10.66M | $98.35M | $106.96M | $113.66M | $92.21M | $58.99M | $4.72M | $83.33K | $125.00K | $83.33K | $338.33K |
| High Forecast | $44.60M | $47.55M | $52.43M | $58.15M | $32.59M | $31.57M | $11.55M | $98.35M | $109.27M | $117.63M | $92.21M | $58.99M | $4.72M | $83.33K | $125.00K | $83.33K | $338.33K |
| Low Forecast | $44.60M | $47.55M | $52.43M | $58.15M | $32.59M | $31.57M | $9.77M | $98.35M | $104.76M | $110.32M | $92.21M | $58.99M | $4.72M | $83.33K | $125.00K | $83.33K | $338.33K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.90% | - | 1.21% | 4.63% | 4.14% | - | - | - |
Amylyx Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 3 analysts is $106.96M, with a low forecast of $104.76M, and a high forecast of $109.27M. AMLX's average Quarter revenue forecast represents a 4.15% increase compared to the company's last Quarter revenue of $102.69M (Sep 23).
Amylyx Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | $18.72M | - | $-2.05M | $-44.59M | $-54.52M | $-54.15M | $-47.78M | $-87.91M |
| Avg Forecast | $-34.74M | $-37.05M | $-40.85M | $-45.30M | $-25.39M | $-24.60M | $-8.31M | $-76.62M | $-83.33M | $-88.55M | $-71.84M | $-45.95M | $-3.68M | $-64.92K | $-97.38K | $-36.31M | $-263.58K |
| High Forecast | $-34.74M | $-37.05M | $-40.85M | $-45.30M | $-25.39M | $-24.60M | $-7.61M | $-76.62M | $-81.61M | $-85.94M | $-71.84M | $-45.95M | $-3.68M | $-64.92K | $-97.38K | $-29.05M | $-263.58K |
| Low Forecast | $-34.74M | $-37.05M | $-40.85M | $-45.30M | $-25.39M | $-24.60M | $-9.00M | $-76.62M | $-85.13M | $-91.64M | $-71.84M | $-45.95M | $-3.68M | $-64.92K | $-97.38K | $-43.57M | $-263.58K |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.21% | - | 0.04% | 12.12% | 839.74% | 556.04% | 1.32% | 333.52% |
3 analysts predict AMLX's average Quarter EBITDA for Dec 23 to be $-83.33M, with a high of $-81.61M and a low of $-85.13M. This is -545.12% lower than Amylyx Pharmaceuticals's previous annual EBITDA (Sep 23) of $18.72M.
Amylyx Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | $20.89M | - | $1.57M | $-42.70M | $-53.76M | $-54.07M | $-47.85M | $-87.90M |
| Avg Forecast | $-22.36M | $-24.44M | $-46.26M | $-44.22M | $-40.68M | $-47.89M | $-49.66M | $-272.10K | $15.50M | $29.76M | $12.92M | $-16.37M | $-55.75M | $-66.09M | $-59.35M | $-36.36M | $-471.75M |
| High Forecast | $-22.36M | $-24.44M | $-46.26M | $-44.22M | $-40.68M | $-42.80M | $-49.66M | $-272.10K | $20.15M | $31.79M | $12.92M | $-16.37M | $-55.75M | $-66.09M | $-59.35M | $-29.09M | $-471.75M |
| Low Forecast | $-22.36M | $-24.44M | $-46.26M | $-44.22M | $-40.68M | $-52.98M | $-49.66M | $-272.10K | $9.30M | $25.03M | $12.92M | $-16.37M | $-55.75M | $-66.09M | $-59.35M | $-43.64M | $-471.75M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.70% | - | -0.10% | 0.77% | 0.81% | 0.91% | 1.32% | 0.19% |
Amylyx Pharmaceuticals's average Quarter net income forecast for Dec 23 is $15.50M, with a range of $9.30M to $20.15M. AMLX's average Quarter net income forecast represents a -25.82% decrease compared to the company's last Quarter net income of $20.89M (Sep 23).
Amylyx Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | $48.72M | - | $44.01M | $40.84M | $29.94M | $29.99M | $26.35M | $38.93M |
| Avg Forecast | $1.50B | $1.60B | $1.76B | $1.96B | $1.10B | $1.06B | $358.59M | $3.31B | $3.60B | $3.82B | $3.10B | $1.98B | $158.87M | $2.80M | $4.20M | $2.80M | $11.38M |
| High Forecast | $1.50B | $1.60B | $1.76B | $1.96B | $1.10B | $1.06B | $388.49M | $3.31B | $3.67B | $3.96B | $3.10B | $1.98B | $158.87M | $2.80M | $4.20M | $2.80M | $11.38M |
| Low Forecast | $1.50B | $1.60B | $1.76B | $1.96B | $1.10B | $1.06B | $328.50M | $3.31B | $3.52B | $3.71B | $3.10B | $1.98B | $158.87M | $2.80M | $4.20M | $2.80M | $11.38M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.01% | - | 0.02% | 0.26% | 10.68% | 7.13% | 9.40% | 3.42% |
Amylyx Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $3.60B, based on 3 Wall Street analysts, with a range of $3.52B to $3.67B. The forecast indicates a 7283.50% rise compared to AMLX last annual SG&A of $48.72M (Sep 23).
Amylyx Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 3 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | $0.31 | - | $0.02 | $-0.65 | $-0.92 | $-0.93 | $-0.93 | $-1.56 |
| Avg Forecast | $-0.33 | $-0.36 | $-0.68 | $-0.65 | $-0.60 | $-0.70 | $-0.73 | $-0.00 | $0.23 | $0.44 | $0.19 | $-0.24 | $-0.82 | $-0.97 | $-0.87 | $-0.69 | $-6.93 |
| High Forecast | $-0.33 | $-0.36 | $-0.68 | $-0.65 | $-0.60 | $-0.63 | $-0.73 | $-0.00 | $0.30 | $0.47 | $0.19 | $-0.24 | $-0.82 | $-0.97 | $-0.87 | $-0.69 | $-6.93 |
| Low Forecast | $-0.33 | $-0.36 | $-0.68 | $-0.65 | $-0.60 | $-0.78 | $-0.73 | $-0.00 | $0.14 | $0.37 | $0.19 | $-0.24 | $-0.82 | $-0.97 | $-0.87 | $-0.69 | $-6.93 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.71% | - | -0.08% | 0.79% | 0.95% | 1.07% | 1.35% | 0.22% |
According to 3 Wall Street analysts, Amylyx Pharmaceuticals's projected average Quarter EPS for Dec 23 is $0.23, with a low estimate of $0.14 and a high estimate of $0.30. This represents a -26.51% decrease compared to AMLX previous annual EPS of $0.31 (Sep 23).
Amylyx Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| PDSB | PDS Bio | $3.00 | $9.00 | 200.00% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
AMLX Forecast FAQ
Is Amylyx Pharmaceuticals a good buy?
Yes, according to 3 Wall Street analysts, Amylyx Pharmaceuticals (AMLX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of AMLX's total ratings.
What is AMLX's price target?
Amylyx Pharmaceuticals (AMLX) average price target is $3.33 with a range of $3 to $4, implying a 27.10% from its last price of $2.62. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Amylyx Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for AMLX stock, the company can go up by 27.10% (from the last price of $2.62 to the average price target of $3.33), up by 52.67% based on the highest stock price target, and up by 14.50% based on the lowest stock price target.
Can Amylyx Pharmaceuticals stock reach $4?
AMLX's average twelve months analyst stock price target of $3.33 does not support the claim that Amylyx Pharmaceuticals can reach $4 in the near future.
What are Amylyx Pharmaceuticals's analysts' financial forecasts?
Amylyx Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $173.18M (high $174.06M, low $172.28M), average EBITDA is $-135M (high $-134M, low $-136M), average net income is $-138M (high $-133M, low $-144M), average SG&A $5.82B (high $5.85B, low $5.79B), and average EPS is $-2.036 (high $-1.961, low $-2.111). AMLX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $202.73M (high $202.73M, low $202.73M), average EBITDA is $-158M (high $-158M, low $-158M), average net income is $-137M (high $-137M, low $-137M), average SG&A $6.82B (high $6.82B, low $6.82B), and average EPS is $-2.018 (high $-2.018, low $-2.018).
Did the AMLX's actual financial results beat the analysts' financial forecasts?
Based on Amylyx Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $22.23M, beating the average analysts forecast of $5.02M by 343.20%. Apple's EBITDA was $-201M, beating the average prediction of $-40.155M by 401.41%. The company's net income was $-198M, missing the average estimation of $-218M by -8.82%. Apple's SG&A was $127.13M, missing the average forecast of $168.68M by -24.63%. Lastly, the company's EPS was $-3.39, beating the average prediction of $-3.35 by 1.18%. In terms of the last quarterly report (Sep 2023), Amylyx Pharmaceuticals's revenue was $102.69M, missing the average analysts' forecast of $113.66M by -9.65%. The company's EBITDA was $18.72M, missing the average prediction of $-88.547M by -121.14%. Amylyx Pharmaceuticals's net income was $20.89M, missing the average estimation of $29.76M by -29.80%. The company's SG&A was $48.72M, missing the average forecast of $3.82B by -98.73%. Lastly, the company's EPS was $0.31, missing the average prediction of $0.438 by -29.14%